These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
273 related articles for article (PubMed ID: 36264400)
1. Cardiovascular risks associated with Janus kinase inhibitors: peering outside the black box. Misra DP; Pande G; Agarwal V Clin Rheumatol; 2023 Feb; 42(2):621-632. PubMed ID: 36264400 [TBL] [Abstract][Full Text] [Related]
2. Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study. Buch MH; Bhatt DL; Charles-Schoeman C; Giles JT; Mikuls T; Koch GG; Ytterberg S; Nagy E; Jo H; Kwok K; Connell CA; Masri KR; Yndestad A RMD Open; 2024 Apr; 10(2):. PubMed ID: 38609322 [TBL] [Abstract][Full Text] [Related]
3. Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review. Mori S; Ogata F; Tsunoda R Clin Rheumatol; 2021 Nov; 40(11):4457-4471. PubMed ID: 34554329 [TBL] [Abstract][Full Text] [Related]
4. Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a Karpouzas GA; Szekanecz Z; Baecklund E; Mikuls TR; Bhatt DL; Wang C; Sawyerr GA; Chen Y; Menon S; Connell CA; Ytterberg SR; Mortezavi M Ther Adv Musculoskelet Dis; 2023; 15():1759720X231201047. PubMed ID: 37942277 [TBL] [Abstract][Full Text] [Related]
5. Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials. Xie W; Huang Y; Xiao S; Sun X; Fan Y; Zhang Z Ann Rheum Dis; 2019 Aug; 78(8):1048-1054. PubMed ID: 31088790 [TBL] [Abstract][Full Text] [Related]
6. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data. Mease P; Charles-Schoeman C; Cohen S; Fallon L; Woolcott J; Yun H; Kremer J; Greenberg J; Malley W; Onofrei A; Kanik KS; Graham D; Wang C; Connell C; Valdez H; Hauben M; Hung E; Madsen A; Jones TV; Curtis JR Ann Rheum Dis; 2020 Nov; 79(11):1400-1413. PubMed ID: 32759265 [TBL] [Abstract][Full Text] [Related]
7. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance. Charles-Schoeman C; Buch MH; Dougados M; Bhatt DL; Giles JT; Ytterberg SR; Koch GG; Vranic I; Wu J; Wang C; Kwok K; Menon S; Rivas JL; Yndestad A; Connell CA; Szekanecz Z Ann Rheum Dis; 2023 Jan; 82(1):119-129. PubMed ID: 36137735 [TBL] [Abstract][Full Text] [Related]
8. Adverse cardiovascular events in rheumatoid arthritis patients treated with JAK inhibitors: An analysis of postmarketing spontaneous safety reports. Goldman A; Galper BL; Druyan A; Grossman C; Sharif K; Shechtman L; Moshkovits Y; Lahat A; Ben-Zvi I Semin Arthritis Rheum; 2024 Aug; 67():152461. PubMed ID: 38772185 [TBL] [Abstract][Full Text] [Related]
9. Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme. Fleischmann R; Curtis JR; Charles-Schoeman C; Mysler E; Yamaoka K; Richez C; Palac H; Dilley D; Liu J; Strengholt S; Burmester G Ann Rheum Dis; 2023 Sep; 82(9):1130-1141. PubMed ID: 37308218 [TBL] [Abstract][Full Text] [Related]
11. Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors. Weitz JI; Szekanecz Z; Charles-Schoeman C; Vranic I; Sahin B; Paciga SA; Wang Z; Hyde C; Martin DA RMD Open; 2022 Nov; 8(2):. PubMed ID: 36323490 [TBL] [Abstract][Full Text] [Related]
12. Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk-Enriched Rheumatoid Arthritis Patients. Charles-Schoeman C; Fleischmann R; Mysler E; Greenwald M; Ytterberg SR; Koch GG; Bhatt DL; Wang C; Mikuls TR; Chen AS; Connell CA; Woolcott JC; Menon S; Chen Y; Lee K; Szekanecz Z Arthritis Rheumatol; 2024 Aug; 76(8):1218-1229. PubMed ID: 38481002 [TBL] [Abstract][Full Text] [Related]
13. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. Ytterberg SR; Bhatt DL; Mikuls TR; Koch GG; Fleischmann R; Rivas JL; Germino R; Menon S; Sun Y; Wang C; Shapiro AB; Kanik KS; Connell CA; N Engl J Med; 2022 Jan; 386(4):316-326. PubMed ID: 35081280 [TBL] [Abstract][Full Text] [Related]
14. Risk of cancer, cardiovascular disease, thromboembolism, and mortality in patients with rheumatoid arthritis receiving Janus kinase inhibitors: a real-world retrospective observational study using Korean health insurance data. Min HK; Kim H; Jeong HJ; Kim SH; Kim HR; Lee SH; Lee K; Shin SA; Park JH Epidemiol Health; 2023; 45():e2023045. PubMed ID: 37080728 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Tofacitinib, Baricitinib, and Upadacitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Wang F; Sun L; Wang S; Davis JM; Matteson EL; Murad MH; Luo F; Vassallo R Mayo Clin Proc; 2020 Jul; 95(7):1404-1419. PubMed ID: 32499126 [TBL] [Abstract][Full Text] [Related]
16. A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19. Bieber T; Feist E; Irvine AD; Harigai M; Haladyj E; Ball S; Deberdt W; Issa M; Grond S; Taylor PC Adv Ther; 2022 Nov; 39(11):4910-4960. PubMed ID: 36063279 [TBL] [Abstract][Full Text] [Related]
17. Crucial safety issues on Janus kinase inhibitors in rheumatoid arthritis might be associated with the lack of LDL-cholesterol management: a reasoned literature analysis. Corrao S Intern Emerg Med; 2023 Nov; 18(8):2157-2161. PubMed ID: 37898967 [TBL] [Abstract][Full Text] [Related]
18. Persistence of Janus-kinase (JAK) inhibitors in rheumatoid arthritis: Australia wide study. Scheepers L; Yang Y; Chen YL; Jones G Semin Arthritis Rheum; 2024 Feb; 64():152314. PubMed ID: 38029717 [TBL] [Abstract][Full Text] [Related]
19. Janus Kinase Inhibitors in Rheumatoid Arthritis: An Update on the Efficacy and Safety of Tofacitinib, Baricitinib and Upadacitinib. Harrington R; Harkins P; Conway R J Clin Med; 2023 Oct; 12(20):. PubMed ID: 37892827 [TBL] [Abstract][Full Text] [Related]
20. Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register. Meissner Y; Schäfer M; Albrecht K; Kekow J; Zinke S; Tony HP; Strangfeld A RMD Open; 2023 Oct; 9(4):. PubMed ID: 37880180 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]